论文部分内容阅读
目的:探讨贝伐单抗联合化学药物治疗耐药晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效及安全性。方法:对2011年1月至2012年9月收治的9例耐药晚期NSCLC患者给予贝伐单抗联合化疗治疗,其中多西他赛联合贝伐单抗3例、培美曲塞二钠联合贝伐单抗5例、紫杉醇联合贝伐单抗1例。每例患者均完成2个周期以上治疗,观察其近期疗效及安全性。结果:9例患者中,3例部分缓解。无进展生存期2~12个月,总生存期4~16个月。主要不良反应有骨髓抑制、下肢静脉血栓、充血性心力衰竭、血压升高、消化道反应以及脱发。结论:贝伐单抗联合化疗治疗耐药晚期NSCLC取得较好疗效,毒性可以耐受。
Objective: To investigate the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Nine patients with advanced NSCLC who were treated from January 2011 to September 2012 were treated with bevacizumab combined with chemotherapy. Among them, docetaxel combined with bevacizumab in 3 and pemetrexed disodium Bevacizumab in 5 cases, paclitaxel combined with bevacizumab in 1 case. Each patient completed more than 2 cycles of treatment, observation of its immediate effect and safety. Results: Of the 9 patients, 3 were partially relieved. Progressive survival of 2 to 12 months, the total survival of 4 to 16 months. The main adverse reactions were myelosuppression, venous thrombosis of the lower extremities, congestive heart failure, elevated blood pressure, gastrointestinal reactions and alopecia. Conclusion: Bevacizumab combined with chemotherapy has good efficacy in the treatment of advanced NSCLC with drug resistance, and the toxicity can be tolerated.